ストックスクリーナーアプリを入手
3.3548
2.28%
0.0648
前日終値:
$3.29
開ける：
$3.35
24時間の取引高:
1.02M
Relative Volume:
0.50
時価総額：
$348.53M
収益：
-
当期純損益:
$-166.01M
株価収益率:
-1.6146
EPS:
-2.0778
ネットキャッシュフロー:
$-131.32M
1週間 パフォーマンス:
+10.33%
1か月 パフォーマンス:
+6.15%
6か月 パフォーマンス:
-1.61%
1年 パフォーマンス:
+5.16%
1日の値動き範囲:
$3.21
$3.39
1週間の範囲:
$3.01
$3.39
52週間の値動き範囲:
$2.715
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
名前
Larimar Therapeutics Inc
セクター
電話
844-511-9056
住所
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.355 | 341.77M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
524.31 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.45 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.81 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-29 | 開始されました | Truist | Buy |
| 2024-10-16 | 開始されました | Oppenheimer | Outperform |
| 2024-10-03 | 開始されました | Wedbush | Outperform |
| 2024-10-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-03 | 開始されました | Leerink Partners | Outperform |
| 2023-11-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-19 | 開始されました | Guggenheim | Buy |
| 2022-02-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-02-01 | 開始されました | William Blair | Outperform |
すべてを表示
Larimar Therapeutics Inc (LRMR) 最新ニュース
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - Stocktwits
Here’s What Citi Thinks About Larimar Therapeutics (LRMR) - Yahoo Finance
H.C. Wainwright initiates Larimar stock coverage with buy rating - Investing.com UK
LRMR Assumed by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
H.C. Wainwright initiates Larimar stock coverage with buy rating By Investing.com - Investing.com South Africa
Price to book forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Larimar Therapeutics Up Nearly 32%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk - Moomoo
Baird Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $5 - Moomoo
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's AtaxiaSlideshow (NASDAQ:LRMR) 2026-07-01 - Seeking Alpha
Enterprise value to EBIT forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Moomoo
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
LRMR Maintains by Baird -- Price Target Lowered to $5.00 - GuruFocus
A Quick Look at Today's Ratings for Larimar Therapeutics(LRMR.US), With a Forecast Between $5 to $25 - Moomoo
Larimar Therapeutics: Late-Stage FA Program Advances Amid Execution Risks (NASDAQ:LRMR) - Seeking Alpha
Larimar Therapeutics submits rolling BLA for nomlabofusp - The Pharma Letter
Buy Recommendation for Larimar Therapeutics (LRMR) Following Mar - GuruFocus
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2500 Growth Benchmark - marketscreener.com
Larimar Therapeutics (LRMR) Faces Stock Decline After Safety Fin - GuruFocus
LRMR Stock Dips As Traders Weigh Cash Runway And Volatility - StocksToTrade
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp in Friedreich’s ataxia - grafa.com
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug - Benzinga
LRMR Stock Slides As Traders Eye Cash Runway And Volatility - StocksToTrade
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR) - Yahoo Finance
Larimar submits first module of rolling BLA for nomlabofusp - Investing.com UK
LRMR Stock Holds Support As Biotech Traders Watch Cash Runway - timothysykes.com
Why is Larimar Therapeutics stock sliding today? By Investing.com - Investing.com India
Why is Larimar Therapeutics stock sliding today? - Investing.com
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Benchmark Index - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Larimar Therapeutics stock tumbles after clinical data release By Investing.com - Investing.com Nigeria
Larimar Therapeutics stock tumbles after clinical data release - Investing.com
Larimar Therapeutics Submits First Module of Rolling Bla and Reports Positive Open Label Data for Nomlabofusp in Friedreich?S Ataxia - marketscreener.com
Larimar Therapeutics (LRMR) Submits First Module for Accelerated Approval - GuruFocus
Larimar Advances Nomlabofusp BLA Toward Accelerated Approval - TipRanks
Larimar submits first module of rolling BLA for nomlabofusp By Investing.com - Investing.com South Africa
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2000 Growth Benchmark - marketscreener.com
LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and strong regulatory progress - TradingView
Larimar Therapeutics submits first module of rolling BLA after positive nomlabofusp open‑label data - TradingView
LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and advances toward accelerated approval - TradingView
Larimar says FDA can review nomlabofusp for accelerated approval - Stock Titan
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000E Growth Benchmark - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell 3000 Value Benchmark - marketscreener.com
Larimar Therapeutics, Inc. (LRMR) Investigation: Bronstein, Gewir - The National Law Review
Larimar Therapeutics to host investor event on Monday By Investing.com - Investing.com South Africa
Larimar Therapeutics Inc (LRMR) 財務データ
収益
当期純利益
現金流量
EPS
Larimar Therapeutics Inc (LRMR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hamilton Thomas Edward | Director |
Feb 27 '26 |
Buy |
5.00 |
100,000 |
500,000 |
664,798 |
| THOMAS FRANK E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
7,000 |
| SHERMAN JEFFREY W | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
5,000 |
| Flynn James E | Director |
Jul 31 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
9,538,945 |
2.18%
2.70%
大文字化:
|
ボリューム (24 時間):